Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording of Post Earning Conference Call held on 30th October 202330-10-2023
30-10-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication for Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2023 - Regulation 30 and 47 of SEBI LODR28-10-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for financial and operational performance for quarter and half year ended September 30, 202328-10-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release for Unaudited Financial Results for quarter ended September 30, 202328-10-2023
Shalby Ltd - 540797 - Our CMD Dr. Vikram Shah Honored With Prestigious 'Healthcare Personality Of The Year Award 2023 By FICCI
Our CMD, Dr. Vikram Shah honored with Prestigious "Healthcare Personality of the Year Award 2023" by FICCI27-10-2023
Shalby Ltd - 540797 - Board Meeting Outcome for Outcome Of Board Meeting - Financial Results For Quarter And Half Year Ended September 30, 2023
Outcome of Board Meeting - Financial Results For Quarter and Half Year Ended September 30, 202327-10-2023
Shalby Ltd - 540797 - Financial Results For Quarter And Half Year Ended September 30, 2023
Financial Results for Quarter and Half Year ended September 30, 202327-10-2023
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Conference call to discuss Unaudited Financial Results for quarter ended September 30, 202320-10-2023
Shalby Ltd - 540797 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For Quarter Ended September 30, 2023
Shalby Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 ,inter alia, to consider and approve Unaudited Standalone And Consolidated Financial Results For Quarter Ended September 30, 202319-10-2023